Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Tolaney Details IHC Testing Considerations for HER2-Low TNBC and Data on ADCs

July 29th 2024

Sara M. Tolaney, MD, MPH, shares biopsy considerations when determining HER2-low status for patients with TNBC and details data within the TNBC landscape.

Tarantino Talks Limitations in HER2-Low Breast Cancer Management, Key Advancements in HER2+/TNBC

July 28th 2024

Paolo Tarantino, MD, discusses current treatment landscapes and looks to the future in HER2-low breast cancer, HER2-positive breast cancer, and TNBC.

From Targetless to Targetable, Breakthroughs Push Forward in TNBC Treatment Landscape

July 26th 2024

Sara M. Tolaney, MD, MPH, discusses the transformation of treatments for patients with triple-negative breast cancer.

Changes in HER2+ Breast Cancer May Include Tailored Therapy With pCR, Use of T-DXd

July 26th 2024

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.

MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer

July 25th 2024

Lajos Pusztai, MD, DPhil, discusses molecular residual disease monitoring in early-stage breast cancer.

Dr Thompson on Trials Evaluating De-Escalated Treatment in Early-Stage Breast Cancer

July 24th 2024

Alastair Thompson, BSc, MBChB, MD, FRCS, discusses ongoing trials evaluating de-escalated treatment in early-stage breast cancer.

Pending Dato-DXd Approval Solidifies Importance of Sequencing in HR+ Breast Cancer

July 24th 2024

Paolo Tarantino, MD, discusses questions about the optimal sequencing of antibody-drug conjugates in endocrine-refractory, HR-positive breast cancer.

Novel Prompt Shows Potential to Decrease Overtreatment in Older Patients With Early-Stage Breast Cancer

July 24th 2024

An EHR-based prompt or “nudge” decreased the rates of sentinel lymph node biopsy among older patients with early-stage breast cancer.

Dr Brufsky on the Unique Design of the Allogeneic SV-BR-1-GM Vaccine in Metastatic Breast Cancer

July 24th 2024

Adam M. Brufsky, MD, PhD, FACP, discusses the unique design of the allogeneic GM-CSF–secreting breast cancer vaccine SV-BR-1-GM.

Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast Cancer

July 24th 2024

Sara M. Tolaney, MD, MPH, discusses the potential role for biomarkers in guiding treatment decisions in early-stage HER2-positive breast cancer.

Dr Shah on Research to Minimize Surgical Intervention in Locoregional Breast Cancer

July 23rd 2024

Chirag Shah, MD, discusses ongoing clinical trials aiming to minimize surgical intervention in locoregional breast cancer.

Crofelemer Misses Diarrhea End Point in Patients With Solid Tumors Receiving Targeted Therapy

July 23rd 2024

Crofelemer did not improve the incidence of diarrhea in patients with solid tumors receiving targeted therapy.

Dr Mouabbi on Clinical Trials for Invasive Lobular Breast Cancer

July 23rd 2024

Jason A. Mouabbi, MD, discusses clinical trials aimed at expanding the treatment paradigm for invasive lobular breast cancer.

DESTINY-Breast03 and DESTINY-Breast06 Data Shape Metastatic Breast Cancer Treatment

July 23rd 2024

Paolo Tarantino MD, and V. K. Gadi, MD, PhD discuss data from DESTINY-Breast03 and DESTINY-Breast06.

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

July 22nd 2024

Sonya Reid, MD, MPH, discusses barriers to universal germline testing utilization in breast cancer, particularly among underserved populations.

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management

July 22nd 2024

Circulating tumor DNA is in constant flux, rendering its evaluation potentially useful in metastatic breast cancer management.

V. Craig Jordan, PhD, the ‘Father of Tamoxifen,’ Dies at 76

July 22nd 2024

V. Craig Jordan, PhD, of The University of Texas MD Anderson Cancer Center and a pioneer in the field of breast cancer, died on June 9, 2024.

Combinations and Treatment Sequence Strategies in Breast Cancer

July 22nd 2024

In their discussion, the key opinion leaders explore the potential of combination therapies in HR+/HER2- metastatic breast cancer, with a specific focus on the ELECTRA study, which investigated the combination of elacestrant and abemaciclib.

PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors

July 22nd 2024

The expert panel examines the subgroup data from the postMONARCH study, focusing on patients with ESR1 and PIK3CA mutations, and emphasizes the important role of CDK4/6 inhibitors in the treatment of these specific patient populations with HR+/HER2- metastatic breast cancer.

Dr Gandhi on Considerations for Continuing CDK4/6 Inhibitors After Progression in HR+ Advanced Breast Cancer

July 22nd 2024

Shipra Gandhi, MD, discusses considerations for continuing with a CDK4/6 inhibitor or switching therapies in HER2- negative advanced breast cancer.